Jason Brayer, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

JasonBrayerMDPhD

Oncology Tampa, FL

Hematologic Oncology

Assistant Member

Overview of Dr. Brayer

Dr. Jason Brayer is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute.

Education & Training

  • University of South Florida Morsani College of Medicine
    University of South Florida Morsani College of MedicineFellowship, Hematology/Oncology, 2011 - 2015
  • University of South Florida Morsani College of Medicine
    University of South Florida Morsani College of MedicineResidency, Internal Medicine, 2009 - 2011
  • University of South Florida Morsani College of Medicine
    University of South Florida Morsani College of MedicineClass of 2009
  • H Lee Moffitt Cancer Center & Research InstitutePost-Doctoral Fellowship, Immunology, 2002 - 2005
  • La Jolla Institute of Allergy & ImmunologyPost-Doctoral Fellowship, Division of Immune Regulation, 2000 - 2002

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2011 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...
    Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
    Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
    Jason B. Brayer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

Hospital Affiliations